Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease in which loss of tolerance to nuclear self-antigens leads to autoantibody production, immune-complex formation, and inflammatory injury across many organ systems. Its course is characteristically relapsing and remitting, and its clinical expression is highly heterogeneous, ranging from skin and joint involvement to potentially organ- and life-threatening kidney and central nervous system disease.

Definition

Systemic lupus erythematosus is an autoimmune connective tissue disease defined by the presence of antinuclear antibodies together with immune-mediated injury to multiple organ systems, including the skin, joints, kidneys, blood cells, serosal membranes, and nervous system.

Scope

This entry covers SLE as a clinical and conceptual entity within the systemic autoimmune diseases: the breakdown of immune tolerance, the prototypical antinuclear and anti-double-stranded-DNA autoantibodies, the type I interferon signature, the pattern of multi-organ involvement, and how classification criteria are used in research. It is reference-educational and does not provide diagnostic or treatment instructions.

Key concepts

• Loss of tolerance to nuclear self-antigens
• Antinuclear antibodies (ANA)
• Anti-double-stranded-DNA and anti-Smith antibodies
• Immune-complex deposition
• Type I interferon signature
• Lupus nephritis as a major organ manifestation
• Disease activity versus accrued damage
• Classification criteria versus clinical diagnosis

Mechanisms

In SLE, defective clearance of apoptotic material exposes nuclear antigens, and impaired immune tolerance permits autoreactive B and T cells to drive production of antinuclear antibodies, including the relatively specific anti-double-stranded-DNA and anti-Smith antibodies. These autoantibodies form immune complexes that deposit in tissues such as the renal glomeruli and activate complement and inflammatory pathways. A prominent type I interferon signature, driven in part by nucleic-acid sensing, amplifies the autoimmune response and is a hallmark of the disease (Tsokos, 2011; Lisnevskaia et al., 2014). The resulting injury produces the characteristic multi-organ phenotype.

Clinical relevance

SLE is the prototypical systemic autoimmune disease and a reference point for understanding autoantibody-driven, multi-organ illness; its features such as malar rash, arthritis, cytopenias, nephritis, and serositis illustrate how immune-complex disease manifests clinically. The classification criteria developed by EULAR and the ACR are designed to define homogeneous study populations rather than to diagnose individuals (Aringer et al., 2019). This entry describes the disease conceptually and is not a basis for individual diagnostic or therapeutic decisions.

Epidemiology

SLE shows a striking female predominance, typically around nine women affected for every man, with onset most often in the reproductive years. Incidence and prevalence vary substantially by ancestry, with higher frequency and often greater severity reported in populations of African, Hispanic, and Asian descent compared with European-ancestry populations (Tsokos, 2011; Lisnevskaia et al., 2014).

Evidence & guidelines

Classification of SLE for research uses the 2019 EULAR/ACR criteria, which require a positive antinuclear antibody test as an entry criterion and then weight clinical and immunologic items (Aringer et al., 2019). These criteria standardize study populations and should not be equated with clinical diagnosis. Management recommendations are issued by EULAR and the ACR and are summarized in disease-specific guidelines rather than in this overview.

History

Lupus was long recognized as a skin disease, and the discovery of the LE cell in 1948 and of antinuclear antibodies in the 1950s established its systemic, autoimmune nature. Successive classification systems, from the American Rheumatism Association criteria through the SLICC criteria to the 2019 EULAR/ACR criteria, reflect the evolving understanding of the disease's serology and organ involvement.

Debates

Should SLE be regarded as one disease or a spectrum of overlapping endotypes?

The marked heterogeneity of organ involvement, autoantibody profiles, and the interferon signature has prompted debate over whether SLE is a single entity or a cluster of molecularly distinct subsets, which has implications for trial design and targeted therapy.

Key figures

• George Tsokos
• David Isenberg
• Martin Aringer

Seminal works

• tsokos-2011
• aringer-2019
• lisnevskaia-2014

Frequently asked questions

What autoantibodies are characteristic of SLE?

Antinuclear antibodies are nearly universal, while anti-double-stranded-DNA and anti-Smith antibodies are more specific for the disease and are part of its classification criteria.

Do classification criteria diagnose lupus?

No. Criteria such as the 2019 EULAR/ACR criteria are designed to define consistent populations for research; clinical diagnosis is made by a clinician integrating the full clinical picture.